Why Analysts See Mersana's Story Shifting To Deal And CVR Outcomes After $1B Buyout [Yahoo! Finance]
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: Yahoo! Finance
up to roughly 7.06 %, underscoring how closely the stock is now tethered to the pending acquisition terms and CVR dynamics. With revenue growth assumptions holding near 13.86 % and long term expectations anchored in the combined entity's prospects, analyst sentiment has largely shifted to a neutral, wait and see posture that weighs immediate cash value against longer dated milestone risk. Stay tuned to learn how you can track these evolving assumptions and the shifting deal driven narrative around Mersana in the months ahead. Stay updated as the Fair Value for Mersana Therapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Mersana Therapeutics. ?? Bullish Takeaways Oppenheimer highlights that Day One is effectively paying up to $285M for Mersana, implying a roughly 280 % premium to pre deal levels and signaling that Day One management sees differentiated value in the Emi Le B7 H4 ADC despite alternati
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSNPR Newswire
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)GlobeNewswire
- Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their RightsGlobeNewswire
- Mersana Therapeutics (NASDAQ:MRSN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- How Mersana's Acquisition Is Changing the Story and Analyst Outlook for Investors [Yahoo! Finance]Yahoo! Finance
MRSN
Earnings
- 11/14/25 - Miss
MRSN
Sec Filings
- 12/5/25 - Form SC
- 12/5/25 - Form SC
- 12/4/25 - Form SC
- MRSN's page on the SEC website